Skip to content

Arvinas ARVN PP&E (Net)

PP&E (Net) at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$21.7M+17.6%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$41.62M-15.4%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$28.41M-3.2%
Immunome logo
ImmunomeIMNM
$17.08M+55.9%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$3.2M-42.4%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$38M-17.4%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's PP&E (net)?
Arvinas (ARVN) reported PP&E (net) of $5.5M in Q1 2026.
How has Arvinas's PP&E (net) changed year-over-year?
Arvinas's PP&E (net) decreased by 17.9% year-over-year, from $6.7M to $5.5M.
What is the long-term trend for Arvinas's PP&E (net)?
Over 5 years (2020 to 2025), Arvinas's PP&E (net) has grown at a -15.8% compound annual growth rate (CAGR), from $12.3M to $5.2M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.